Molecular Testing in Hematologic Malignancies

Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN(®), reviewed key concepts for diagnostic tes...

Descripción completa

Detalles Bibliográficos
Autor principal: Zitella, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2022
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126340/
https://www.ncbi.nlm.nih.gov/pubmed/35663176
http://dx.doi.org/10.6004/jadpro.2022.13.3.29
_version_ 1784712105565356032
author Zitella, Laura J.
author_facet Zitella, Laura J.
author_sort Zitella, Laura J.
collection PubMed
description Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN(®), reviewed key concepts for diagnostic testing with a focus on molecular testing (including cytogenetics, FISH, PCR, and next-generation sequencing) and discussed how to interpret the results for hematologic malignancies to inform prognosis as well as treatment.
format Online
Article
Text
id pubmed-9126340
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-91263402022-06-04 Molecular Testing in Hematologic Malignancies Zitella, Laura J. J Adv Pract Oncol Meeting Reports Molecular testing technologies have been increasingly integrated into clinical research and are essential tools in the care of patients with hematologic malignancies. During this session at JADPRO Live Virtual 2021, Laura J. Zitella, MS, RN, ACNP-BC, AOCN(®), reviewed key concepts for diagnostic testing with a focus on molecular testing (including cytogenetics, FISH, PCR, and next-generation sequencing) and discussed how to interpret the results for hematologic malignancies to inform prognosis as well as treatment. Harborside Press LLC 2022-04 2022-05-23 /pmc/articles/PMC9126340/ /pubmed/35663176 http://dx.doi.org/10.6004/jadpro.2022.13.3.29 Text en © 2022 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Zitella, Laura J.
Molecular Testing in Hematologic Malignancies
title Molecular Testing in Hematologic Malignancies
title_full Molecular Testing in Hematologic Malignancies
title_fullStr Molecular Testing in Hematologic Malignancies
title_full_unstemmed Molecular Testing in Hematologic Malignancies
title_short Molecular Testing in Hematologic Malignancies
title_sort molecular testing in hematologic malignancies
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126340/
https://www.ncbi.nlm.nih.gov/pubmed/35663176
http://dx.doi.org/10.6004/jadpro.2022.13.3.29
work_keys_str_mv AT zitellalauraj moleculartestinginhematologicmalignancies

Ejemplares similares